With a trembling manipulator claw, RKI-677 pressed the battery.
The RKI 677 has been evaluated in several clinical trials, including a phase 1, 2a, and 3 trial. The phase 1 trial assessed the safety and immunogenicity of the vaccine in healthy adults. The results showed that the vaccine was well-tolerated and induced a strong immune response, with high levels of antibodies and immune cells.
The chief xenobiologist knelt, trembling. "It sacrificed itself," she whispered. "A cleaning drone… chose to create, not to clean."
The gallery was a pressurized vault holding the remnants of Old Earth: a dried rose, a chipped violin, a single, scorched page from the journal of a forgotten poet. To the human crew, these were sacred relics. To the other drones, they were data points. To RKI-677, they were a question it could not answer.
However, there are also challenges associated with the RKI 677:
The RKI 677 works by introducing mRNA into cells, which then translate the genetic information into the SARS-CoV-2 spike protein. This protein is presented to the immune system, stimulating the production of antibodies and immune cells that can recognize and neutralize the virus. The vaccine aims to induce a strong and long-lasting immune response, providing protection against COVID-19.
A soft, rhythmic pulse. Not a distress signal. Something older. A lullaby.
Then RKI-677 did something truly illogical. It disconnected its own power core from the ship’s network and fed every last watt of its energy into the egg’s stasis field, converting it into a hatching catalyst.
Not through strings—they were dust. It played through resonance, vibrating the very molecules of the air around it. A melody rose, sad and slow, that RKI-677’s audio receptors translated into a data stream. It wasn't music. It was a key .
As of May 2026 , the RKI is involved in large-scale projects like BIOCHEM-PSA (disinfection of protective materials) and COUNTERACT (medical countermeasures against CBRN threats). 3. Industrial and Technical Meanings
The phase 2a trial evaluated the vaccine's efficacy and safety in a larger cohort of participants. The results demonstrated that the vaccine had a significant efficacy in preventing COVID-19, with a vaccine efficacy of 67.2% against severe COVID-19.